Biopsy Devices Market Size By Product (Biopsy Guidance Systems [Manual, Robotic], Needle Based Biopsy Guns [Vacuum-Assisted, Fine Needle, Core Needle] Biopsy Devices [Disposable, Reusable], Biopsy Forceps [General Biopsy, Hot Biopsy]), By End-use (Hospitals, Ambulatory Surgical Centers), Regional Outlook, Industry Analysis Report, Growth Potential, Competitive Market Share & Forecast, 2023 – 2032

Industry Statistics

Biopsy Devices Market size exceeded USD 2 billion in 2022 and is anticipated to depict over 6% CAGR through 2023-2032, as a result of the increasing prevalence of breast cancer.
 

Get more details on this report - Request Free Sample PDF
 

Awareness about cancer and its diagnosis has risen, given the introduction of numerous educational campaigns. The risk of breast cancer has also surged over the years. As per the American Cancer Society’s report, in the U.S., a woman is at a 12% lifetime risk of breast cancer. These factors will boost the requirement for biopsy equipment and supplies to remove small pieces of breast tissue to detect cancer cells. The general population is also becoming conscious of innovative diagnostic equipment availability, thereby boosting the development of breast biopsy devices.
 

However, randomized trials have indicated the complications associated with product use. For instance, a trial conducted in Europe revealed major issues related to prostate needle biopsy including fever episodes, urinary tract infection, transitory bacteremia, urinary retention, and sepsis. Moreover, excessive bleeding, drainage from biopsy sites, and swelling due to infections or sepsis are also presented among users, thereby limiting the use of needle biopsy devices to some extent.
 

Rising prevalence of eczema and other skin disorders to drive biopsy forceps adoption

Get more details on this report - Request Free Sample PDF
 

Biopsy devices market value from the biopsy forceps segment will reach over USD 170 million by 2032, on account of the surge in cases of skin disorders including eczema. Based on statistics from the National Eczema Association, 1 in 10 individuals is estimated to develop eczema in their lifetime, with high prevalence during early childhood. Furthermore, there has been an increase in the number of biopsy procedures among patients with skin disorders. These factors, alongside the introduction of superior products for convenient and rapid sample collection, will stimulate the use of equipment such as biopsy forceps.
 

Diversified & economical service delivery fuels biopsy device use in ambulatory surgical centers

Get more details on this report - Request Free Sample PDF
 

The biopsy devices market share from the ambulatory surgery center end-user segment is set to depict over 7.5% CAGR through 2023-2032, given the affordability and the delivery of a range of healthcare services through ASCs. According to data from the Centers for Medicare & Medicaid Services, the number of these surgical centers rises by 1.7% annually on average. Procedures or services have also grown at an annual rate of 2.7% over recent years. These factors will encourage more patients to opt for biopsy procedures in ambulatory surgical centers and consequently drive the use of biopsy devices.
 

Improved access to infectious disease treatment spurs product usage in North America

Get more details on this report - Request Free Sample PDF
 

North America region held over 52% share of the global biopsy devices market in 2022, due to the established healthcare infrastructure. With the rising burden of infectious diseases, point-of-care diagnostic devices have also gained massive acceptance for early and safe disease detection. In addition, developed insurance and co-payment systems have established a strong presence across the region. Furthermore, the availability of major industry players will proliferate biopsy equipment development across the region.
 

Middle East and Africa biopsy devices market value is also anticipated to cross USD 110 million by 2032, considering the introduction of government initiatives to support cancer patients. For instance, in December 2021, the Ministry of Health and Prevention, Merck Serono Middle East, and Al Manzil healthcare services inked a partnership to aid cancer patients with limited access to health insurance. Various manufacturers and non-government organizations have also acquired advanced tech to assist health service organizations, thus bolstering biopsy device development in the region.
 

Strategic mergers and acquisitions to define global industry landscape

Medtronic plc, Olympus Corporation, Boston Scientific Corporation, Becton, Dickinson and Company (BD), FUJIFILM Holdings Corporation, Argon Medical Devices, Cardinal Health, Hologic Inc., Inc, B. Braun Melsungen AG, Cook Group Incorporated, Devicor Medical Products, Inc. (Danaher Corporation), INRAD Inc, and Stryker Corporation are some of the key players operating in the global biopsy devices market. These companies are focusing on mergers and acquisitions and other strategies to strengthen their presence in the industry.
 

For instance, in January 2021, Hologic acquired SOMATEX Medical Technologies GmbH, a developer of Biopsy Site Markers and Localization Technologies. The acquisition was intended to help the company expand its product portfolio and sustain its market position.
 

Impact of COVID-19 crisis on biopsy devices market trends

Lockdowns and stringent regulations imposed during the COVID-19 pandemic asserted a profound impact on the world economy and industry verticals, including healthcare. In April 2020, radiology practices, academic radiology departments, and the entire healthcare sector witnessed financial repercussions. During the initial months of the pandemic, breast screening programs were also discontinued in countries including England. These factors may have reduced the acceptance of biopsy diagnostic procedures among cancer patients and consequently hindered industry expansion to a certain extent.
 

The biopsy devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments:

By Product

• Biopsy guidance systems
  • Manual
  • Robotic
• Needle based biopsy guns
  • Vacuum-assisted biopsy (VAB) devices
  • Fine needle aspiration biopsy (FNAB) devices
  • Core needle biopsy (CNB) devices
• Biopsy needles
  • Disposable
  • Reusable
• Biopsy forceps
  • General biopsy forceps
  • Hot biopsy forceps
• Others
  • Brushes
  • Curettes
  • Punches

By End-use

• Hospitals
• Ambulatory surgical center
• Others

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Others
• Asia Pacific
  • Japan
  • China
  • India
  • Others
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Others
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • Others